Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for Trials

Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.

Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses large studies and their tendencies to not group patients by subtypes. Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.